KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Debt (2020 - 2025)

Historic Total Debt for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q3 2025 value amounting to $11.2 million.

  • Supernus Pharmaceuticals' Total Debt fell 7588.07% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 7588.07%. This contributed to the annual value of $47.3 million for FY2024, which is 908.39% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Total Debt stood at $11.2 million, which was down 7588.07% from $30.0 million recorded in Q1 2025.
  • Supernus Pharmaceuticals' 5-year Total Debt high stood at $424.1 million for Q4 2021, and its period low was $11.2 million during Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Total Debt value was $46.7 million (recorded in 2022), while the average stood at $100.2 million.
  • Over the last 5 years, Supernus Pharmaceuticals' Total Debt had its largest YoY gain of 160317.35% in 2022, and its largest YoY loss of 9501.99% in 2022.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Total Debt stood at $424.1 million in 2021, then plummeted by 95.02% to $21.1 million in 2022, then surged by 146.54% to $52.1 million in 2023, then fell by 9.08% to $47.3 million in 2024, then plummeted by 76.27% to $11.2 million in 2025.
  • Its Total Debt stands at $11.2 million for Q3 2025, versus $30.0 million for Q1 2025 and $47.3 million for Q4 2024.